Comment from Pfizer Inc.

Summary: Pfizer Inc. supports the FDA's efforts to identify drug repurposing candidates and suggests a systematic, evidence-based approach that leverages existing data. They advocate for structured mechanisms for early engagement, potential economic incentives (like priority review vouchers or tax deductions), and multi-stakeholder collaboration to overcome limited commercial incentives for repurposing off-patent drugs.